×
About 125,090 results

ALLMedicine™ Type 2 Diabetes Center

Research & Reviews  40,180 results

Efficacy and Tolerability of Evogliptin in Patients with Type 2 Diabetes Mellitus: A Sy...
https://doi.org/10.1016/j.clinthera.2021.06.001
Clinical Therapeutics; Oh H, Nguyen HD et. al.

Jul 26th, 2021 - Evogliptin is one of the latest dipeptidyl peptidase-4 (DPP-4) inhibitor, and a number of clinical trials have been performed following its development, including several randomized controlled trials (RCTs) performed to evaluate its efficacy and t...

Quantitative proteomic analysis of human peripheral nerves from subjects with type 2 di...
https://doi.org/10.1111/dme.14658
Diabetic Medicine : a Journal of the British Diabetic Ass... Ising E, Åhrman E et. al.

Jul 26th, 2021 - Diabetic peripheral neuropathy (DPN) is a common and severe complication to type 2 diabetes (T2D). The pathogenesis of DPN is not fully known, but several pathways and gene polymorphisms contributing to DPN are described. DPN can be studied using ...

A retrospective nationwide study on the trends in first-line antidiabetic medication fo...
https://doi.org/10.1111/jdi.13636
Journal of Diabetes Investigation; Bouchi R, Sugiyama T et. al.

Jul 26th, 2021 - To investigate the national trend in the prescription of first-line non-insulin antidiabetic agents and total medical costs (TMCs) after prescribing the drug in Japanese patients with type 2 diabetes. Using the National Database of Health Insuranc...

Hb A2-Calderdale δ2(NA2)His→Asn; HBD: c.7C>A and Misdiagnosis of Type 2 Diabetes Mellit...
https://doi.org/10.1080/03630269.2021.1954945
Hemoglobin Stangerup I, Petersen J et. al.

Jul 26th, 2021 - The Hb A2-Calderdale variant [δ2(NA2)His→Asn, HBD: c.7C>A] was described as a novel variant in 2014. However, a high performance liquid chromatography (HPLC) peak was never identified indicating that this fraction could be 'hiding' somewhere else ...

Intravenous fosfomycin as salvage therapy for osteomyelitis caused by multidrug-resista...
https://doi.org/10.1093/ajhp/zxab294
American Journal of Health-system Pharmacy : AJHP : Offic... Wong M, Wong D et. al.

Jul 26th, 2021 - A case of osteomyelitis caused by multidrug-resistant (MDR) Pseudomonas aeruginosa is reported. An 84-year-old Caucasian male with an underlying history of type 2 diabetes, peripheral vascular disease, and coronary artery disease had chronic nonhe...

see more →

Guidelines  47 results

Latin American Association for the study of the liver (ALEH) practice guidance for the ...
https://doi.org/10.1016/j.aohep.2020.09.006
Annals of Hepatology; Arab JP, Dirchwolf M et. al.

Oct 8th, 2020 - Non-alcoholic fatty liver disease (NAFLD) currently represents an epidemic worldwide. NAFLD is the most frequently diagnosed chronic liver disease, affecting 20-30% of the general population. Furthermore, its prevalence is predicted to increase ex...

Walking for subjects with type 2 diabetes: A systematic review and joint AMD/SID/SISMES...
https://doi.org/10.1016/j.numecd.2020.08.021
Nutrition, Metabolism, and Cardiovascular Diseases : NMCD; Moghetti P, Balducci S et. al.

Oct 1st, 2020 - Regular exercise is considered a cornerstone in the management of type 2 diabetes mellitus (T2DM). It improves glucose control and cardiovascular risk factors, contributes to weight loss, and also improves general well-being, likely playing a role...

Pharmacologic Approaches to Glycemic Treatment of Type 2 Diabetes: Synopsis of the 2020...
https://doi.org/10.7326/M20-2470
Annals of Internal Medicine; Doyle-Delgado K, Chamberlain JJ et. al.

Aug 31st, 2020 - The American Diabetes Association (ADA) updates the Standards of Medical Care in Diabetes annually to provide clinicians, patients, researchers, payers, and other interested parties with evidence-based recommendations for the diagnosis and managem...

2020 Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduc...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7545583
Journal of the American College of Cardiology; Das SR, Everett BM et. al.

Aug 10th, 2020 - 2020 Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes: A Report of the American College of Cardiology Solution Set Oversight Committee.|2020|Das SR,Everett BM,Birtcher KK,Brown...

3. Prevention or Delay of Type 2 Diabetes: Standards of Medical Care in Diabetes-2020.
https://doi.org/10.2337/dc20-S003
Diabetes Care;

Dec 21st, 2019 - The American Diabetes Association (ADA) "Standards of Medical Care in Diabetes" includes the ADA's current clinical practice recommendations and is intended to provide the components of diabetes care, general treatment goals and guidelines, and to...

see more →

Drugs  1,363 results see all →

Clinicaltrials.gov  2,886 results

Effect of Short-Term Beta-Cell Rest in Adolescents and Young Adults With Type 2 Diabetes Mellitus
https://clinicaltrials.gov/ct2/show/NCT00445627

May 7th, 2020 - Background: Type 2 diabetes mellitus (T2DM) is a condition characterized by insulin resistance and progressive failure of the insulin-secreting beta-cells. Previously considered a disease of adults, it is now becoming increasingly prevalent in chi...

Genetics of Obesity, Diabetes, and Heart Disease in African Diaspora Populations
https://clinicaltrials.gov/ct2/show/NCT01316783

May 7th, 2020 - This research protocol is designed to study the genetic basis of the clustering of several metabolic disorders including Type 2 diabetes (T2D), hypertension, cardiovascular diseases (CVD), obesity, and other related conditions in populations of th...

Fibre Grain Herb Trial in Type 2 Diabetes
https://clinicaltrials.gov/ct2/show/NCT02553382

May 6th, 2020 - Despite the availability of multiple medications for the treatment of Type 2 diabetes, patients often continue to have difficulty attaining blood glucose targets and managing cardiovascular disease risk factors. Recent trends in non-pharmacologica...

Efficacy and Bone Safety of Sotagliflozin Dose 1 and Dose 2 Versus Placebo in Subjects With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control
https://clinicaltrials.gov/ct2/show/NCT03386344

May 5th, 2020 - Study duration per participant is approximately 110 weeks (Screening period of up to 2 weeks, 2 week single-blind run-in period), a 26-week double-blind core treatment period, a 78-week double-blind extension period, and a 2- week post treatment f...

Efficacy and Safety of Sotagliflozin Versus Placebo and Empagliflozin in Subjects With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control While Taking a DPP4 Inhibitor Alone or With Metf...
https://clinicaltrials.gov/ct2/show/NCT03351478

May 5th, 2020 - Up to 34 weeks, including a Screening Phase of up to 2 weeks, a 2 week Run-In Phase, a 26-week double-blind Treatment Period and a 4-week post-treatment Follow-up Period to collect safety information.

see more →

News  5,513 results

Cycling Linked to Longer Life in People With Type 2 Diabetes
https://www.medscape.com/viewarticle/955071

Jul 19th, 2021 - Bicycle riding may help people with diabetes live longer, new research suggests. Among more than 7,000 adults with diabetes in 10 Western European countries followed for about 15 years, those who cycled regularly were significantly less likely to ...

Fast Five Quiz: Type 2 Diabetes and Heart Failure
https://www.medscape.com/viewarticle/940633

Jul 14th, 2021 - The increased prevalence of type 2 diabetes and heart failure highlights the need for optimal strategies for comanaging these diseases. An estimated 26.9 million Americans, or 8.2% of the US population, have diabetes; an additional 6.2 million hav...

With Tirzepatide, a 'Great Future' for Patients With T2D
https://www.medscape.com/viewarticle/954345

Jul 14th, 2021 - This transcript has been edited for clarity. I'm here to talk about tirzepatide, a dual GIP/GLP-1 receptor agonists that's under investigation for the management of type 2 diabetes, obesity, and fatty liver disease. We're all very used to GLP-1 re...

New Agents for Youth-Onset Type 2 Diabetes 'Finally in Sight'
https://www.medscape.com/viewarticle/954680

Jul 12th, 2021 - Dr Kenneth C. Copeland There are limited treatment options for children and youth with type 2 diabetes, but a few novel therapies beyond metformin are on the horizon, experts told the virtual American Diabetes Association (ADA) 81st Scientific Ses...

Dulaglutide Tied to Lower Incidence of Erectile Dysfunction in Type 2 Diabetes
https://www.medscape.com/viewarticle/954532

Jul 11th, 2021 - NEW YORK (Reuters Health) - Men with type 2 diabetes randomly assigned to dulaglutide versus placebo had a lower incidence of erectile dysfunction, an exploratory analysis showed. "The finding that dulaglutide reduced the occurrence of moderate or...

see more →

Patient Education  47 results see all →